Exelixis
EXEL
#1725
Rank
C$13.65 B
Marketcap
$47.83
Share price
-1.16%
Change (1 day)
53.35%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): C$0.81 Billion

According to Exelixis's latest financial reports the company's current earnings are C$2.08 Billion. In 2023 the company made an earning of C$0.37 Billion, an increase over its 2022 earnings that were of C$0.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) C$0.81 B119.85%
2023 C$0.37 B9.89%
2022 C$0.33 B-20.33%
2021 C$0.42 B124.82%
2020 C$0.18 B-67.14%
2019 C$0.57 B-11.94%
2018 C$0.64 B185.09%
2017 C$0.22 B-325.82%
2016 -C$0.11 Billion-58.12%
2015 -C$0.25 Billion-37.61%
2014 -C$0.39 Billion9.75%
2013 -C$0.36 Billion65.96%
2012 -C$0.22 Billion-291.63%
2011 C$0.11 B-195.59%
2010 -C$0.12 Billion-42.17%
2009 -C$0.21 Billion-18.98%
2008 -C$0.25 Billion-6.99%
2007 -C$0.27 Billion46.3%
2006 -C$0.19 Billion33.25%
2005 -C$0.14 Billion-30.92%
2004 -C$0.2 Billion44.29%
2003 -C$0.14 Billion12.86%
2002 -C$0.13 Billion22.79%
2001 -C$98.63 Million60.14%
2000 -C$61.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
C$5.99 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$10.64 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
C$21.51 B 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$9.89 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.72 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
C$26.42 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
C$9.97 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$64.39 Million-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$41.73 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA